Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 4 080 JPY -0.49% Market Closed
Market Cap: 317.1B JPY
Have any thoughts about
Hisamitsu Pharmaceutical Co Inc?
Write Note

Hisamitsu Pharmaceutical Co Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hisamitsu Pharmaceutical Co Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Accrued Liabilities
ÂĄ1.3B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Takeda Pharmaceutical Co Ltd
TSE:4502
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hisamitsu Pharmaceutical Co Inc
Glance View

Market Cap
299.2B JPY
Industry
Pharmaceuticals

In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.

Intrinsic Value
4 342.46 JPY
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Hisamitsu Pharmaceutical Co Inc's Accrued Liabilities?
Accrued Liabilities
1.3B JPY

Based on the financial report for Aug 31, 2024, Hisamitsu Pharmaceutical Co Inc's Accrued Liabilities amounts to 1.3B JPY.

What is Hisamitsu Pharmaceutical Co Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-2%

Over the last year, the Accrued Liabilities growth was 7%. The average annual Accrued Liabilities growth rates for Hisamitsu Pharmaceutical Co Inc have been 3% over the past three years , and -2% over the past ten years .

Back to Top